Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the company’s new directions saying, “We have put together a product development plan that no longer depends on just one drug use indication with all of the associated risks and uncertainties. We now have four strategic pillars: Cosmetic with Dermacyte and related products, Topical Applications including wound care, Clinical Applications including TBI, and Devices including our VitaVent invention.”

“Our clinical and topical development lines now include fifteen important potential applications,” he continued. “Before the end of the year, we plan to file an IND with the U.S. FDA for Oxycyte emulsion as a treatment for Carbon Monoxide poisoning. In addition, we plan to expand our cosmetic line rapidly in 2010. It’s all part of our strategy to become a multi-product company with a clearly visible path for growth.”

Oxygen Biotherapeutics, Inc. is a company dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company’s products are based upon core technologies that include biomedical applications for PFCs (perfluorocarbons) as well as medical and industrial applications for biosensors. Oxygen Biotherapeutics has product candidates in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds, ulcers, and cosmetic applications.

Let us hear your thoughts:

Last 5 posts by QualityStocks

• View Systems (VSYM.OB) Up Almost 150% After Coverage by QualityStocks Newsletter - November 24th, 2009
• Consorteum Holdings, Inc. (CSRH.OB) Offers Right Source Solutions in the Payments and Transactions Industry - November 24th, 2009
• Some Options as the US Dollar Continues its Slide - November 24th, 2009
• Newport Digital Technologies (NPDT.OB) Has a Competitive Edge - November 24th, 2009
• Small Cap Voice Featured Company: DecisionPoint Systems, Inc. (DNPI.OB) - November 24th, 2009